RYVU revenue for the last year amounted to 67.15 M PLN, the most of which — 46.86 M PLN — came from its highest performing source at the moment, Novel Small Molecule Therapies, the year earlier bringing 38.95 M PLN. The greatest contribution to the revenue figure was made by European Union Countries — last year it brought RYVU 41.66 M PLN, and the year before that — 24.62 M PLN.